EC approves argenx’s efgartigimod alfa for CIDP treatment
The European Commission (EC) has approved argenx’s Vyvgart (efgartigimod alfa) 1000mg as a single agent for subcutaneous injection to treat…
All articles by Gullapalli Prasanna
Gullapalli Prasanna
-
-
Novartis’ ribociclib approved in Canada for early breast cancer
Health Canada has granted a notice of compliance for Novartis Canada’s Kisqali (ribociclib tablets) plus an aromatase inhibitor for the…
-
Actio gains $66m to advance small molecule therapeutics pipeline
US-based Actio Biosciences has closed a Series B financing round, raising $66m to advance the genetics-driven small molecule therapeutics pipeline…
-
Tisento’s MELAS treatment receives fast track status from FDA
Tisento Therapeutics has received fast track designation from the US Food and Drug Administration (FDA) for its investigational oral medicine,…
-
Averoa secures EC authorisation for oral CKD treatment
The European Commission (EC) has granted marketing authorisation for Averoa's oral therapy Xoanacyl for chronic kidney disease (CKD), a condition…
-
FDA approves MSD’s Keytruda to treat head and neck cancer
MSD has received US Food and Drug Administration (FDA) approval for its anti-programmed death receptor-1 (PD-1) therapy, Keytruda (pembrolizumab), for…
-
Bharat Biotech acquires licence for GSK’s Shigella vaccine development
GSK has licensed altSonflex1-2-3, its Shigella vaccine candidate, to Bharat Biotech for continued development and distribution in low and middle-income…
-
FDA approves label expansion of AbbVie hepatitis C therapy
The US Food and Drug Administration (FDA) has approved the label expansion of AbbVie’s Mavyret (glecaprevir/pibrentasvir) for treating adults and paediatric…
-
Enterome to advance EO2463 immunotherapy with $19m funding
Enterome has secured $19m in new private funding to progress its EO2463 OncoMimics immunotherapy, targeting indolent non-Hodgkin's lymphoma (iNHL). The…
-
SpliceBio secures $135m for gene therapy development
SpliceBio has closed a Series B financing round, raising $135m for the clinical development of SB-007, its gene therapy candidate…